There is no excerpt because this is a protected post.
Protected: Arcellx Announces Kate Aiken as Chief People Officer
Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer
Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, is a highly regarded medical and research professional in infectious diseases with over 25 years of industry experience
Margia Argüello Appointed as Sr. Business Development Manager, BioHealth and Life Sciences, Office of Strategic Industries and Entrepreneurship at Maryland Department of Commerce
The Maryland Department of Commerce has appointed Margia Argüello as Sr. Business Development Manager, BioHealth and Life Sciences, Office of Strategic Industries and Entrepreneurship. She has been tasked with cultivating and coordinating opportunities to expand, retain, and attract biohealth and life sciences businesses in Maryland. This includes the development and implementation of programs and initiatives to address the needs of the industry, such as talent attraction and workforce development; capital investment activity expansion; as well as technology transfer and commercialization strategies. Margia will also be working closely with entrepreneurs, start-ups, and early-stage life sciences companies to navigate the resources available to them throughout the Maryland life sciences ecosystem.
Judy Costello Appointed as Special Projects Manager, Office of the County Executive at Montgomery County, Maryland
The Office of the County Executive at Montgomery County, Maryland recently announced the appointment of Judy Costello as Special Projects Manager. As Special Projects Manager, Judy supports a wide range of business and economic development-related projects (i.e., business/large employer recruitment and retention, education and workforce, small business and innovation, climate change, and transportation). Her focus covers multiple industries within the County.
miRecule Names J&J Pharma Vet Fu-An Kang to Lead Growing Research Team
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule after serving for 6 years as the Senior Director of Chemistry at Abzena, a leading chemistry, biologics and antibody-drug conjugate (ADC) research organization.
Early Charm Announces Hiring of Dan Keeley to Lead Newly Formed Lankenau Ventures
Early Charm, a venture studio that converts science to business, today announced the hiring of Dan Keeley to lead Lankenau Ventures, a new joint venture with Early Charm that aims to accelerate development and commercialization of medical inventions conceived by frontline healthcare workers.
The Center for Breakthrough Medicines at Discovery Labs Appoints Matthew Snyder as Associate Director, Engineering & Facilities
The Center for Breakthrough Medicines at Discovery Labs, an ecosystem accelerating the path to commercialization for cell and gene therapy companies, has appointed Matthew Snyder to the role of Associate Director, Engineering & Facilities. Mr. Snyder will be responsible for establishing the critical support services necessary for laboratory and manufacturing operations. These include setup of a comprehensive safety program; implementation of equipment tracking and maintenance and calibration management systems; interface coordination between site infrastructure utilities, building monitoring and process control systems; and technical engineering support for process operations and facility design.
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President, Corporate Affairs. Mr. Rubin will be responsible for all corporate communications, along with involvement in investor and capital markets activities. He joins NexImmune with more than 20 years of experience in investor relations, investment banking and capital markets within the biotechnology sector.
Arcellx Appoints Neeraj Teotia as Chief Commercial Officer
Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs.
Arcellx Appoints Dr. Christopher Heery as Chief Medical Officer
Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s leadership team. Dr. Christopher Heery has been named Chief Medical Officer (CMO) where he will have responsibility for clinical, regulatory and medical affairs.